The inducible costimulator augments Tc17 cell responses to self and tumor tissue

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1737-1747

  Nelson, Michelle H ^a   Kundimi, Sreenath ^a   Bowers, Jacob S ^a   Rogers, Carolyn E ^a   Huff, Logan W ^a   Schwartz, Kristina M ^a   Thyagarajan, Krishnamurthy ^a   Little, Elizabeth C ^a   Mehrotra, Shikhar ^a   Cole, David J ^a   Rubinstein, Mark P ^a   Paulos, Chrystal M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD39 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 9; ICOS PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE VITILIGO; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; IN VITRO STUDY; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; UPREGULATION; VITILIGO; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS;

EID: 84922576110     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401082     Document Type: Article

References (62)

1. Intlekofer, A. M., A. Banerjee, N. Takemoto, S. M. Gordon, C. S. Dejong, H. Shin, C. A. Hunter, E. J. Wherry, T. Lindsten, and S. L. Reiner. 2008. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 321: 408-411.
2. Hamada, H., Mde. L. Garcia-Hernandez, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton. 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182: 3469-3481.
3. Kondo, T., H. Takata, F. Matsuki, and M. Takiguchi. 2009. Cutting edge: phe-notypic characterization and differentiation of human CD8+ T cells producing IL-17. J. Immunol. 182: 1794-1798.
4. Huber, M., S. Heink, H. Grothe, A. Guralnik, K. Reinhard, K. Elflein, T. Hünig, H. W. Mittrücker, A. Brüstle, T. Kamradt, and M. Lohoff. 2009. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 39: 1716-1725.
5. Tzartos, J. S., M. A. Friese, M. J. Craner, J. Palace, J. Newcombe, M. M. Esiri, and L. Fugger. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172: 146-155.
6. Res, P. C., G. Piskin, O. J. de Boer, C. M. van der Loos, P. Teeling, J. D. Bos, and M. B. Teunissen. 2010. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5: e14108.
7. Eysteinsdóttir, J. H., B. Sigurgeirsson, J. H. Ólafsson, T. Fridriksson, B. A. Agnarsson, S. Davíosson, H. Valdimarsson, and B. R. Lúovíksson. 2013. The role of Th17/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic response. Scand. J. Immunol. 78: 529-537.
8. Ciric, B., M. El-behi, R. Cabrera, G. X. Zhang, and A. Rostami. 2009. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J. Immunol. 182: 5296-5305.
9. Saxena, A., S. Desbois, N. Carrié, M. Lawand, L. T. Mars, and R. S. Liblau. 2012. Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. J. Immunol. 189: 3140-3149.
10. -/- mice. J. Leukoc. Biol. 87: 301-308.
11. Hinrichs, C. S., A. Kaiser, C. M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z. A. Borman, P. Muranski, and N. P. Restifo. 2009. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
12. Huber, M., S. Heink, A. Pagenstecher, K. Reinhard, J. Ritter, A. Visekruna, A. Guralnik, N. Bollig, K. Jeltsch, C. Heinemann, et al. 2013. IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Invest. 123: 247-260.
13. Manel, N., D. Unutmaz, and D. R. Littman. 2008. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9: 641-649.
14. Yang, L., D. E. Anderson, C. Baecher-Allan, W. D. Hastings, E. Bettelli, M. Oukka, V. K. Kuchroo, and D. A. Hafler. 2008. IL-21 and TGF-βeta are required for differentiation of human T(H)17 cells. Nature 454: 350-352.
15. Volpe, E., N. Servant, R. Zollinger, S. I. Bogiatzi, P. Hupé, E. Barillot, and V. Soumelis. 2008. A critical function for transforming growth factor-beta, in-terleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9: 650-657.
16. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
17. Ito, T., S. Hanabuchi, Y. H. Wang, W. R. Park, K. Arima, L. Bover, F. X. Qin, M. Gilliet, and Y. J. Liu. 2008. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28: 870-880.
18. Paulos, C. M., C. Carpenito, G. Plesa, M. M. Suhoski, A. Varela-Rohena, T. N. Golovina, R. G. Carroll, J. L. Riley, and C. H. June. 2010. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci. Transl. Med. 2: 55ra78.
19. Bauquet, A. T., H. Jin, A. M. Paterson, M. Mitsdoerffer, I. C. Ho, A. H. Sharpe, and V. K. Kuchroo. 2009. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat. Immunol. 10: 167-175.
20. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
21. de Wit, J., Y. Souwer, A. J. van Beelen, R. de Groot, F. J. Muller, H. Klaasse Bos, T. Jorritsma, M. L. Kapsenberg, E. C. de Jong, and S. M. van Ham. 2011. CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood 118: 6107-6114.
22. Klebanoff, C. A., Z. Yu, L. N. Hwang, D. C. Palmer, L. Gattinoni, and N. P. Restifo. 2009. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood 114: 1776-1783.
23. Takahashi, N., K. Matsumoto, H. Saito, T. Nanki, N. Miyasaka, T. Kobata, M. Azuma, S. K. Lee, S. Mizutani, and T. Morio. 2009. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J. Immunol. 182: 5515-5527.
24. Moore, T. V., B. S. Clay, C. M. Ferreira, J. W. Williams, M. Rogozinska, J. L. Cannon, R. A. Shilling, A. L. Marzo, and A. I. Sperling. 2011. Protective effector memory CD4 T cells depend on ICOS for survival. PLoS ONE 6: e16529.
25. Hirahara, K., K. Ghoreschi, A. Laurence, X. P. Yang, Y. Kanno, and J. J. O'Shea. 2010. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev. 21: 425-434.
26. Ivanov, I. I., L. Zhou, and D. R. Littman. 2007. Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19: 409-417.
27. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
28. Witsch, E. J., M. Peiser, A. Hutloff, K. Büchner, B. G. Dorner, H. Jonuleit, H. W. Mages, and R. A. Kroczek. 2002. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur. J. Immunol. 32: 2680-2686.
29. Yu, X. Z., Y. Liang, R. I. Nurieva, F. Guo, C. Anasetti, and C. Dong. 2006. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J. Immunol. 176: 7394-7401.
30. Paulos, C. M., and C. H. June. 2010. Putting the brakes on BTLA in T cellmediated cancer immunotherapy. J. Clin. Invest. 120: 76-80.
31. Ford, M. L., A. B. Adams, and T. C. Pearson. 2014. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat. Rev. Nephrol. 10: 14-24.
32. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4: 336-347.
33. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646.
34. Chalmin, F., G. Mignot, M. Bruchard, A. Chevriaux, F. Végran, A. Hichami, S. Ladoire, V. Derangère, J. Vincent, D. Masson, et al. 2012. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36: 362-373.
35. Yu, Y., H. I. Cho, D. Wang, K. Kaosaard, C. Anasetti, E. Celis, and X. Z. Yu. 2013. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J. Immunol. 190: 1873-1881.
36. Kroczek, R. A., H. W. Mages, and A. Hutloff. 2004. Emerging paradigms of T-cell co-stimulation. Curr. Opin. Immunol. 16: 321-327.
37. Paulos, C. M., C. Wrzesinski, A. Kaiser, C. S. Hinrichs, M. Chieppa, L. Cassard, D. C. Palmer, A. Boni, P. Muranski, Z. Yu, et al. 2007. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117: 2197-2204.
38. Ng Tang, D., Y. Shen, J. Sun, S. Wen, J. D. Wolchok, J. Yuan, J. P. Allison, and P. Sharma. 2013. Increased frequency of ICOS+ CD4 T cells as a pharmacody-namic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1: 229-234.
39. Muranski, P., Z. A. Borman, S. P. Kerkar, C. A. Klebanoff, Y. Ji, L. Sanchez-Perez, M. Sukumar, R. N. Reger, Z. Yu, S. J. Kern, et al. 2011. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35: 972-985.
40. Lu, Y., B. Hong, H. Li, Y. Zheng, M. Zhang, S. Wang, J. Qian, and Q. Yi. 2014. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc. Natl. Acad. Sci. USA 111: 2265-2270.
41. Purwar, R., C. Schlapbach, S. Xiao, H. S. Kang, W. Elyaman, X. Jiang, A. M. Jetten, S. J. Khoury, R. C. Fuhlbrigge, V. K. Kuchroo, et al. 2012. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 18: 1248-1253.
42. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
43. Lexberg, M. H., A. Taubner, I. Albrecht, I. Lepenies, A. Richter, T. Kamradt, A. Radbruch, and H. D. Chang. 2010. IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur. J. Immunol. 40: 3017-3027.
44. Lee, Y. K., H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
45. Kryczek, I., E. Zhao, Y. Liu, Y. Wang, L. Vatan, W. Szeliga, J. Moyer, A. Klimczak, A. Lange, and W. Zou. 2011. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3: ra100.
46. Mukasa, R., A. Balasubramani, Y. K. Lee, S. K. Whitley, B. T. Weaver, Y. Shibata, G. E. Crawford, R. D. Hatton, and C. T. Weaver. 2010. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 32: 616-627.
47. Muranski, P., and N. P. Restifo. 2013. Essentials of Th17 cell commitment and plasticity. Blood 121: 2402-2414.
48. Bailey, S. R., M. H. Nelson, R. A. Himes, Z. Li, S. Mehrotra, and C. M. Paulos. 2014. Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5: 276.
49. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
50. Huang, J., Q. J. Wang, S. Yang, Y. F. Li, M. El-Gamil, S. A. Rosenberg, and P. F. Robbins. 2011. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J. Immunother. 34: 327-335.
51. Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. Almeida, E. Gostick, Z. Yu, C. Carpenito, et al. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17: 1290-1297.
52. Martin-Orozco, N., Y. Li, Y. Wang, S. Liu, P. Hwu, Y. J. Liu, C. Dong, and L. Radvanyi. 2010. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 70: 9581-9590.
53. Weber, J. 2010. Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37: 430-439.
54. Carthon, B. C., J. D. Wolchok, J. Yuan, A. Kamat, D. S. Ng Tang, J. Sun, G. Ku, P. Troncoso, C. J. Logothetis, J. P. Allison, and P. Sharma. 2010. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial. Clin. Cancer Res. 16: 2861-2871.
55. Fu, T., Q. He, and P. Sharma. 2011. The ICOS/ICOSL pathway is required for optimal anti-tumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 71: 5445-5454.
56. Simpson, T. R., S. A. Quezada, and J. P. Allison. 2010. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 22: 326-332.
57. Fan, X., S. A. Quezada, M. A. Sepulveda, P. Sharma, and J. P. Allison. 2014. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211: 715-725.
58. Al-Khami, A. A., S. Mehrotra, and M. I. Nishimura. 2011. Adoptive immuno-therapy of cancer: Gene transfer of T cell specificity. Self Nonself 2: 80-84.
59. Kohn, D. B., G. Dotti, R. Brentjens, B. Savoldo, M. Jensen, L. J. Cooper, C. H. June, S. Rosenberg, M. Sadelain, and H. E. Heslop. 2011. CARs on track in the clinic. Mol. Ther. 19: 432-438.
60. Greenberg, P. D., R. J. Finch, M. A. Gavin, M. Kalos, D. A. Lewinsohn, M. Lonergan, J. D. Lord, B. H. Nelson, C. Ohlén, A. P. Sing, et al. 1998. Genetic modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J. Sci. Am. 4(Suppl. 1): S100-S105.
61. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
62. Sadelain, M. 2009. T-cell engineering for cancer immunotherapy. Cancer J. 15: 451-455.